Bluebird says gene therapy application delayed again, citing disagreement with FDA

Discussions between Bluebird and the FDA are hung up on a release assay, data from which would be included in the company's application. 

Bluebird says gene therapy application delayed again, citing disagreement with FDA
Discussions between Bluebird and the FDA are hung up on a release assay, data from which would be included in the company's application.